BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12780786)

  • 1. HLA-DRB1*16-restricted recognition of myeloid cells, including CD34+ CML progenitor cells.
    Ebeling SB; Ivanov R; Hol S; Aarts TI; Hagenbeek A; Verdonck LF; Petersen EJ
    Br J Haematol; 2003 Jun; 121(5):721-9. PubMed ID: 12780786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactive CD4+ T lymphocytes can exert cytotoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen.
    Jiang YZ; Mavroudis D; Dermime S; Hensel N; Couriel D; Molldrem J; Barrett AJ
    Br J Haematol; 1996 Jun; 93(3):606-12. PubMed ID: 8652381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
    Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
    Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
    Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
    Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
    Bosch GJ; Joosten AM; Kessler JH; Melief CJ; Leeksma OC
    Blood; 1996 Nov; 88(9):3522-7. PubMed ID: 8896419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
    Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
    Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
    Sun JY; Senitzer D; Forman SJ; Chatterjee S; Wong KK
    Cancer Immunol Immunother; 2003 Dec; 52(12):761-70. PubMed ID: 14564482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation.
    Smit WM; Rijnbeek M; van Bergen CA; Fibbe WE; Willemze R; Falkenburg JH
    Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10152-7. PubMed ID: 9707616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
    de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
    J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
    Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel minor histocompatibility antigens responsible for graft-versus-leukemia (GVL) effect on chronic myeloid leukemia: usefulness of determining the clonotype of T cells associated with GVL effect after donor leukocyte infusion.
    Nakao S
    Int J Hematol; 2002 Aug; 76 Suppl 1():274-6. PubMed ID: 12430863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation.
    Chen J; Schmitt A; Bunjes D; Chen B; Schmitt M
    Int J Oncol; 2007 May; 30(5):1119-27. PubMed ID: 17390013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors.
    Pawelec G; Max H; Halder T; Bruserud O; Merl A; da Silva P; Kalbacher H
    Blood; 1996 Sep; 88(6):2118-24. PubMed ID: 8822931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study on T lymphocyte recognition of tumor antigens on autologous CML cells].
    Chen Y; Hao Y; You S; Wei D; Wei D; Liao X; Ding S; Liu S; Wei D
    Zhonghua Xue Ye Xue Za Zhi; 1997 Dec; 18(12):638-41. PubMed ID: 15625763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein.
    Yong AS; Stephens N; Weber G; Li Y; Savani BN; Eniafe R; Keyvanfar K; Kurlander R; Rezvani K; Barrett AJ
    Leukemia; 2011 Apr; 25(4):629-37. PubMed ID: 21252986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic characterization of normal and CML CD34-positive cells: only the most primitive CML progenitors include Ph-neg cells.
    De Fabritiis P; Dowding C; Bungey J; Chase A; Angus G; Szydlo R; Goldman JM
    Leuk Lymphoma; 1993 Sep; 11(1-2):51-61. PubMed ID: 7693107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.
    Rezvani K; Grube M; Brenchley JM; Sconocchia G; Fujiwara H; Price DA; Gostick E; Yamada K; Melenhorst J; Childs R; Hensel N; Douek DC; Barrett AJ
    Blood; 2003 Oct; 102(8):2892-900. PubMed ID: 12829610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
    Yong AS; Keyvanfar K; Hensel N; Eniafe R; Savani BN; Berg M; Lundqvist A; Adams S; Sloand EM; Goldman JM; Childs R; Barrett AJ
    Blood; 2009 Jan; 113(4):875-82. PubMed ID: 18922853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
    Wysoczanska B; Bogunia-Kubik K; Dlubek D; Jaskula E; Sok A; Drabczak-Skrzypek D; Sedzimirska M; Lange A
    Transplant Proc; 2007 Nov; 39(9):2898-901. PubMed ID: 18022011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA class II restricted T-cell reactivity to a developmentally regulated antigen shared by leukemic cells and CD34+ early progenitor cells.
    Mutis T; Schrama E; van Luxemburg-Heijs SA; Falkenburg JH; Melief CJ; Goulmy E
    Blood; 1997 Aug; 90(3):1083-90. PubMed ID: 9242539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.